1. Home
  2. USAU vs TRDA Comparison

USAU vs TRDA Comparison

Compare USAU & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U.S. Gold Corp.

USAU

U.S. Gold Corp.

N/A

Current Price

$8.40

Market Cap

242.1M

ML Signal

N/A

TRDA

Entrada Therapeutics Inc.

N/A

Current Price

$4.65

Market Cap

275.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
USAU
TRDA
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
242.1M
275.3M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
USAU
TRDA
Price
$8.40
$4.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
★ $26.50
$17.75
AVG Volume (30 Days)
153.1K
★ 449.9K
Earning Date
12-09-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 36.11
N/A
EPS
★ N/A
N/A
Revenue
$17,402,000.00
★ $25,421,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$361.69
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$9.55
$4.11
52 Week High
$23.72
$16.45

Technical Indicators

Market Signals
Indicator
USAU
TRDA
Relative Strength Index (RSI) 27.43 44.20
Support Level N/A $4.18
Resistance Level $16.65 $5.13
Average True Range (ATR) 0.69 0.51
MACD -0.12 0.05
Stochastic Oscillator 1.26 23.15

Price Performance

Historical Comparison
USAU
TRDA

About USAU U.S. Gold Corp.

U.S. Gold Corp is a gold, copper and precious metals development and exploration company pursuing exploration opportunities mainly in Wyoming, Nevada and Idaho. It is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada and the Challis Gold Project in Idaho. The company is engaged in the exploration and evaluation of its mineral properties, which is the single operating segment.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: